Inclusion Criteria - ANZCTR
Investigator Led Study of Intravenous Milrinone in Heart Failure with Preserved Ejection Fraction (HFpEF). IV Mil for HFpEFProtocol No: MilHFpEF-IV-02Version: 1Date: 14th May 2019Investigator LedCHANGESInvestigator led not sponsorAlfred will own data, Cardiora will have access to results upon request8 patients, 6 active, 2 control. 25mcg IV Mil.INVESTIGATOR SIGNATURE PAGEBy signing this Protocol, the Investigator acknowledges and agrees:The Protocol contains all necessary details for conducting the study. The Investigator will conduct this study as detailed herein, in compliance with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) ADDIN EN.CITE <EndNote><Cite><Year>July 2000</Year><RecNum>108</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>108</rec-number><foreign-keys><key app="EN" db-id="zxw92ws0s2tazmewpzdx5fzn5e2d9wdwvsvz" timestamp="1481024795">108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title>Note for Guidance on Good Clinical Practice (CPMP/GCP/135/95) and Note for Guidance on Good Clinical Practice (CPMP/GCP/135/95) annotated with Therapeutic Goods Administration (TGA) comments 
</title><secondary-title>DSEB</secondary-title></titles><periodical><full-title>DSEB</full-title></periodical><dates><year>July 2000</year></dates><urls></urls></record></Cite></EndNote>1 and the applicable regulatory requirements, and will make every reasonable effort to complete the study within the time designated.The Protocol and all relevant information on the drug relating to pre-clinical and prior clinical experience will be made available to all physicians, nurses and other personnel who participate in the conducting of this study. The Investigator will discuss this material with them to assure that they are fully informed regarding the drug and the conduct of the study.This document contains information that is privileged or confidential. As such, it may not be disclosed unless specific prior permission is granted in writing by The Investigator or such disclosure is required by federal or other laws or regulations. Persons to whom any of this information is to be disclosed must first be informed that the information is confidential. These restrictions on disclosure will apply equally to all future information supplied, which is indicated as privileged or confidential. The conduct and results of this study will be kept confidential. The results of this study may be published. Upon completion of the Study it is the intention of the parties to prepare a joint publication regarding or describing the Study and all the results there from and both parties shall co-operate in this regard. Investigator Name:_________________________________Signature:_________________________________Date: ____________Contact DetailsPrincipal Investigator A/Prof Justin Mariani MDHeart Centre, Alfred HospitalPhone: +614 9076 3263Associate InvestigatorsProf. David Kaye Heart Centre, Alfred HospitalPhone:+61 (0)3 9076 3263Dr Shane Nanayakkara Heart Centre, Alfred HospitalPhone:+61 (0)3 9076 3263Dr Sophie Offen Heart Centre, Alfred HospitalPhone:+61 (0)3 9076 3263Abbreviations and Definitions of TermsACEAngiotensin Converting EnzymeAEAdverse EventARBAngiotensin Receptor BlockersBPBlood PressureBTTBridge to TransplantCADCoronary Artery DiseaseCPBCardio-pulmonary bypassCRFCase Report FormCVPCentral Venous PressureDTDestination TherapyECGElectrocardiogramEDVEnd Diastolic VolumeEDDEnd Diastolic DiameterEFEjection FractioneGFRestimated Glomerular Filtration RateESDEnd Systolic DiameterESVEnd Systolic VolumeGCPGood Clinical PracticeGPGeneral PractitionerICDImplantable Cardioverter DefibrillatorsIRBInstitutional Review BoardIVSIntraventricular SeptumKCCQKansas City Cardiomyopathy QuestionnaireLC/MS/MSLiquid Chromatography-Tandem Mass SpectrometryLHFLeft Heart FailureLVADLeft Ventricular Assist DeviceMAPMean Arterial PressureNT proBNPN-terminal Prohormone of Brain Natriuretic PeptideNYHANew York Heart Association classificationPAPPulmonary Artery PressurePCWPPulmonary Capillary Wedge PressurePICFPatient Informed Consent FormPVRPulmonary Vascular ResistanceRVRight Ventricle RVFRight Ventricular FailureRVSPRight ventricular Systolic PressureSAESerious Adverse EventSIRSSystemic Inflammatory Response SyndromeTAPSETricuspid Annular Plane Systolic ExcursionTEAETreatment Emergent Adverse EventTRTricuspid RegurgitationVADVentricular Assist DeviceVTVentricular TachycardiaVFVentricular FibrillationTable of Contents TOC \o "3-3" \h \z \t "1st section,1,2nd Section,2" 1.Synopsis PAGEREF _Toc8732898 \h 82.Introduction PAGEREF _Toc8732899 \h 122.1.Heart Failure with Preserved Ejection Fraction PAGEREF _Toc8732900 \h 122.2.HFpEF Management PAGEREF _Toc8732901 \h 122.3.Rationale for Performing the Study: PAGEREF _Toc8732902 \h 133.Study Objectives PAGEREF _Toc8732903 \h 133.1.Objectives PAGEREF _Toc8732904 \h 134.Study Description PAGEREF _Toc8732905 \h 145.Study Population PAGEREF _Toc8732906 \h 145.1.Selection Criteria PAGEREF _Toc8732907 \h 145.1.1.Inclusion Criteria PAGEREF _Toc8732908 \h 145.1.2.Exclusion Criteria: PAGEREF _Toc8732909 \h 145.2.Prior and Concomitant Therapies Medications PAGEREF _Toc8732910 \h 156.Investigational Product PAGEREF _Toc8732912 \h 156.1.Description PAGEREF _Toc8732913 \h 156.2.Packaging and Labeling PAGEREF _Toc8732914 \h 156.3.Storage, Dispensing and Reconciliation of Study Drug PAGEREF _Toc8732915 \h 157.Study Endpoints PAGEREF _Toc8732916 \h 157.1.Exploratory PAGEREF _Toc8732917 \h 157.2.Primary (safety) PAGEREF _Toc8732918 \h 168.Study Procedures PAGEREF _Toc8732919 \h 178.1.Exploratory Endpoints PAGEREF _Toc8732920 \h 188.2.Safety Endpoints PAGEREF _Toc8732921 \h 188.3.Study Visits PAGEREF _Toc8732922 \h 198.3.rmed Consent Process PAGEREF _Toc8732923 \h 198.3.2.Screening Visit (Day -28 to Day 1) PAGEREF _Toc8732924 \h 198.3.3.Re-Screens PAGEREF _Toc8732925 \h 208.3.4.Study Day (Day 1) PAGEREF _Toc8732926 \h 208.4.Early termination visit PAGEREF _Toc8732927 \h 209.Adverse Events PAGEREF _Toc8732928 \h 209.1.Definitions PAGEREF _Toc8732929 \h 209.2.Monitoring PAGEREF _Toc8732930 \h 219.2.1.Intensity of Adverse Events PAGEREF _Toc8732931 \h 219.2.2.Relationship to Study Medication PAGEREF _Toc8732932 \h 219.3.Serious Adverse Events PAGEREF _Toc8732933 \h 229.3.1.Reporting of Serious Adverse Events PAGEREF _Toc8732934 \h 229.4.Clinical Laboratory Abnormalities and Other Abnormal Assessments as AEs and SAEs PAGEREF _Toc8732935 \h 2310.Statistical Considerations PAGEREF _Toc8732936 \h 2310.1.Sample size PAGEREF _Toc8732937 \h 2310.1.1.Safety Evaluations PAGEREF _Toc8732938 \h 2310.1.2.Exploratory Evaluations PAGEREF _Toc8732939 \h 2311.Data MANAGEMENT PAGEREF _Toc8732940 \h 2411.1.Source Data and Retention of Records PAGEREF _Toc8732941 \h 2412.Estimated Duration of the Study PAGEREF _Toc8732942 \h 2412.1.Participant Information and Informed Consent PAGEREF _Toc8732943 \h 2413.References PAGEREF _Toc8732944 \h 2414.Appendices PAGEREF _Toc8732945 \h 2814.1.Appendix 1. Patient Informed Consent Template PAGEREF _Toc8732946 \h 28SynopsisStudy Title:Investigator Led Study of Intravenous Milrinone in Heart Failure with Preserved Ejection Fraction (HFpEF). Protocol Number:MilHFpEF-IV-02Development Phase:Phase IbIndication:Efficacy study in HFpEF patientsStudy Drugs:IV milrinone No. Subjects:8 patients (6 treated and 2 placebo)Study Duration:Single day procedureEntire study estimated to be completed in 6 monthsObjectives of the Study:To investigate the effects of intravenous millrinone on rest and exercise hemodynamics in HFPEF patients.Endpoints:Exploratory endpoints:Changes compared to baseline (at rest, 20 W and peak supine exercise) in: Pulmonary capillary wedge pressurePulmonary artery pressures (mean, systolic, diastolic and pulse pressure) and derived parameters including pulmonary arterial compliance and elastanceCardiac output (thermodilution)Systemic blood pressure (measured non-invasively)Peripheral vascular resistanceHeart rateSafety Endpoint:All adverse event (AE) recording and assessments.Study Design:Randomized, double blind, placebo controlledInclusion and Exclusion CriteriaInclusion Criteria: Males and females aged 18-85. Symptoms of heart failure (NYHA class III or ambulatory class IV). Left Ventricular Ejection Fraction (LVEF) ≥50%.Heart Failure hospitalization within 12 months or NT-proBNP >125 pg/mL. Evidence of prior diagnosis of HFpEF, confirmed via: Echocardiographic parameters (one or more of the following) observed//recorded in previous 6 months:septal E/e’ ≥ 13 (a measure of LV filling pressure) orleft atrial volume index > 34ml/m2 or LV mass index ≥ 115 g/m2 (male) or ≥ 95 g/m2 (female). orHemodynamic exercise test within 12 months. Stable medical heart failure therapy including diuretics for 2 weeks.Able to give written informed consent and agree to adhere to all protocol requirements. Potassium between 4 – 5.5mmol/LExclusion Criteria:Myocardial infarction or acute coronary syndromes within 90 days. Hypotension (systolic BP <90 mmHg) at Screening or BaselineSevere Hypertension (systolic BP >180 mmHg) at Screening or BaselinePoorly controlled atrial fibrillation (ventricular rate>120bpm).History of significant ventricular arrhythmia in the past yearSignificant renal impairment (eGFR <30 ml/min/1.73 m2)Severe physical limitation defined by inability to complete a minimum exercise tolerance time of 120 seconds on two treadmill tests within 2 weeks of enrollmentRestrictive or infiltrative cardiomyopathy.PregnancyHistory of allergic reaction to milrinone or any excipients in the study drug. Participation in another clinical trialStudy Overview:This is a phase 1b, exploratory study to evaluate the effect of IV milrinone on exercise hemodynamics. This is a double blinded, placebo-controlled investigator led trial. The study cohort will comprise of 8 patients (6 active, 2 placebo). Subjects who are successfully screened will be enrolled into trial. After baseline evaluation on day 1, subjects will be randomly allocated. After the baseline rest and exercise haemodynamic evaluation, subjects will be randomised to receive either active (milrinone) or placebo (saline) infusion.At the conclusion of the infusion, rest and exercise measures will be repeated. Exercise will be conducted at individual matched workloads and durations1. The primary objective was to compare the between-group changes in exercise hemodynamics after administration of placebo versus milrinone. Parameters to be evaluated are described in the prior sections. Statistical Analyses:Changes invariables described above will be compared using a paired t-testTable SEQ Table \* ARABIC 1: Schedule of ProceduresVisitScreeningStudy day2Timing/windowDay -28 to 1Day 1Informed consentXInclusion/Exclusion criteriaXDemographicsXMedical/medication historyXXphysical examXXVital signsXXNYHA ClassXXHaematologyXBiochemistry, EUC, LFTXXBNP and NT proBNPXXTroponinXX12 Lead ECGXXRest and Exercise Hemodynamic evaluationXPlasma milrinone levels1XAdverse event monitoringX1 To be taken at the end of infusion, and at the end of exercise test. 2 plasma levels will need to be taken2 A focused cardiovascular exam will be conducted at the study visit by the PI or a designated specialist heart failure/LVAD cardiologist at day 1.IntroductionHeart Failure with Preserved Ejection FractionHeart failure (HF) is one of the most common and most disabling forms of cardiovascular disease. Moreover, HF is particularly prevalent in older individuals, affecting up to 10% of the population over 75 years ADDIN EN.CITE <EndNote><Cite><Author>Mosterd</Author><Year>2007</Year><RecNum>71</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>71</rec-number><foreign-keys><key app="EN" db-id="zxw92ws0s2tazmewpzdx5fzn5e2d9wdwvsvz" timestamp="1480385786">71</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mosterd, A.</author><author>Hoes, A. W.</author></authors></contributors><auth-address>Department of Cardiology, Meander Medical Centre, Amersfoort, The Netherlands. a.mosterd@meandermc.nl</auth-address><titles><title>Clinical epidemiology of heart failure</title><secondary-title>Heart</secondary-title></titles><periodical><full-title>Heart</full-title></periodical><pages>1137-46</pages><volume>93</volume><number>9</number><keywords><keyword>Cause of Death</keyword><keyword>Epidemiologic Methods</keyword><keyword>Female</keyword><keyword>Heart Failure/diagnosis/*epidemiology/etiology/prevention & control</keyword><keyword>Hospitalization/statistics & numerical data</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Prognosis</keyword></keywords><dates><year>2007</year><pub-dates><date>Sep</date></pub-dates></dates><isbn>1468-201X (Electronic)
1355-6037 (Linking)</isbn><accession-num>17699180</accession-num><urls><related-urls><url>. From a clinical and epidemiologic point of view it is important to note that the diagnosis of HF is based initially upon the presence of well-recognized symptoms and signs, for example as used in the Framingham criteria ADDIN EN.CITE <EndNote><Cite><Author>McKee</Author><Year>1971</Year><RecNum>72</RecNum><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>72</rec-number><foreign-keys><key app="EN" db-id="zxw92ws0s2tazmewpzdx5fzn5e2d9wdwvsvz" timestamp="1480385813">72</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>McKee, P. A.</author><author>Castelli, W. P.</author><author>McNamara, P. M.</author><author>Kannel, W. B.</author></authors></contributors><titles><title>The natural history of congestive heart failure: the Framingham study</title><secondary-title>N Engl J Med</secondary-title></titles><periodical><full-title>N Engl J Med</full-title></periodical><pages>1441-6</pages><volume>285</volume><number>26</number><keywords><keyword>Adult</keyword><keyword>Age Factors</keyword><keyword>Aged</keyword><keyword>Chronic Disease</keyword><keyword>Coronary Disease/complications</keyword><keyword>Female</keyword><keyword>Follow-Up Studies</keyword><keyword>*Health Surveys</keyword><keyword>*Heart Failure/diagnosis/epidemiology/etiology/mortality/prevention & control</keyword><keyword>Humans</keyword><keyword>Hypertension/complications</keyword><keyword>Male</keyword><keyword>Massachusetts</keyword><keyword>Middle Aged</keyword><keyword>Rheumatic Heart Disease/complications</keyword><keyword>Sex Factors</keyword></keywords><dates><year>1971</year><pub-dates><date>Dec 23</date></pub-dates></dates><isbn>0028-4793 (Print)
0028-4793 (Linking)</isbn><accession-num>5122894</accession-num><urls><related-urls><url>. Subsequent to the clinical diagnosis, the application of diagnostic investigations such as echocardiography can then be used to identify the pathophysiology of the clinical phenotype together with the provision of prognostic and therapeutic information. Amongst the echocardiographic parameters that are applied to the assessment of ventricular function, the ejection fraction remains in common use despite numerous limitations including its sensitivity to loading conditions and technical issues with endocardial border definition and geometric assumptionsPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BdXJpZ2VtbWE8L0F1dGhvcj48WWVhcj4yMDA2PC9ZZWFy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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BdXJpZ2VtbWE8L0F1dGhvcj48WWVhcj4yMDA2PC9ZZWFy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ADDIN EN.CITE.DATA 4, 5. This stated, we now appreciate that approximately 50% of HF patients both in community studies and in registries of patents admitted with acutely decompensated HF have a normal or near normal ejection fraction, termed HF with preserved ejection fraction (HFPEF)PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Pd2FuPC9BdXRob3I+PFllYXI+MjAwNjwvWWVhcj48UmVj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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Pd2FuPC9BdXRob3I+PFllYXI+MjAwNjwvWWVhcj48UmVj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ADDIN EN.CITE.DATA 6, 7. The clinical profile of patients with HFPEF differs substantially to those with reduced ejection fraction HF (HFREF). Patients are older, more likely to be female, more obese, and have different contributing risk factors. Coronary artery disease is less common, whilst rates of hypertension, diabetes, and atrial fibrillation are greaterPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NY011cnJheTwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NY011cnJheTwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+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ADDIN EN.CITE.DATA 8. African Americans may develop HFPEF at a younger age ADDIN EN.CITE <EndNote><Cite><Author>Zile MR</Author><Year>2014</Year><RecNum>128</RecNum><DisplayText><style face="superscript">9</style></DisplayText><record><rec-number>128</rec-number><foreign-keys><key app="EN" db-id="zxw92ws0s2tazmewpzdx5fzn5e2d9wdwvsvz" timestamp="1502947853">128</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Zile MR, Little W</author></authors><secondary-authors><author>Mann, D. L. Zipes D, Libby P, Bonow R</author></secondary-authors></contributors><titles><title>Heart failure with preserved ejection fraction</title><secondary-title>Braunwald's Heart Disease</secondary-title></titles><pages>557-574</pages><volume>10th Edition</volume><dates><year>2014</year></dates><publisher>Elsevier Inc</publisher><urls></urls></record></Cite></EndNote>9. Consistent with the increased age of the population, the rate of non-cardiac comorbidities is also higherPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CdXJzaTwvQXV0aG9yPjxZZWFyPjIwMDY8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CdXJzaTwvQXV0aG9yPjxZZWFyPjIwMDY8L1llYXI+PFJl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ADDIN EN.CITE.DATA 10, including chronic lung disease, anaemia, chronic kidney disease, and malignancy. These co-morbidities are responsible for a significant proportion of the morbidity and mortality associated with HFPEF, although the majority of limitation to exercise intolerance is cardiac ADDIN EN.CITE <EndNote><Cite><Author>Borlaug</Author><Year>2014</Year><RecNum>127</RecNum><DisplayText><style face="superscript">11</style></DisplayText><record><rec-number>127</rec-number><foreign-keys><key app="EN" db-id="zxw92ws0s2tazmewpzdx5fzn5e2d9wdwvsvz" timestamp="1502947286">127</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Borlaug, B. A.</author></authors></contributors><auth-address>The Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic.</auth-address><titles><title>Mechanisms of exercise intolerance in heart failure with preserved ejection fraction</title><secondary-title>Circ J</secondary-title></titles><periodical><full-title>Circ J</full-title></periodical><pages>20-32</pages><volume>78</volume><number>1</number><keywords><keyword>Adult</keyword><keyword>*Exercise</keyword><keyword>*Heart Failure/mortality/pathology/physiopathology</keyword><keyword>Humans</keyword><keyword>*Stroke Volume</keyword></keywords><dates><year>2014</year></dates><isbn>1347-4820 (Electronic)
1346-9843 (Linking)</isbn><accession-num>24305634</accession-num><urls><related-urls><url>. Renal dysfunction, defined as an abnormal glomerular filtration rate (GFR) or as microalbuminuria, has been shown to independently predict changes in left ventricular (LV) geometry, and has been implicated in the pathogenesis of HFPEFPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ccm91d2VyczwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+
PFJlY051bT44MDwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQi
PjEyPC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+ODA8L3JlYy1udW1i
ZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ6eHc5MndzMHMydGF6bWV3cHpk
eDVmem41ZTJkOXdkd3ZzdnoiIHRpbWVzdGFtcD0iMTQ4MDM4NjQ0MyI+ODA8L2tleT48L2ZvcmVp
Z24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNv
bnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkJyb3V3ZXJzLCBGLiBQLjwvYXV0aG9yPjxhdXRo
b3I+ZGUgQm9lciwgUi4gQS48L2F1dGhvcj48YXV0aG9yPnZhbiBkZXIgSGFyc3QsIFAuPC9hdXRo
b3I+PGF1dGhvcj5Wb29ycywgQS4gQS48L2F1dGhvcj48YXV0aG9yPkdhbnNldm9vcnQsIFIuIFQu
PC9hdXRob3I+PGF1dGhvcj5CYWtrZXIsIFMuIEouPC9hdXRob3I+PGF1dGhvcj5IaWxsZWdlLCBI
LiBMLjwvYXV0aG9yPjxhdXRob3I+dmFuIFZlbGRodWlzZW4sIEQuIEouPC9hdXRob3I+PGF1dGhv
cj52YW4gR2lsc3QsIFcuIEguPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRo
LWFkZHJlc3M+RGVwYXJ0bWVudCBvZiBDYXJkaW9sb2d5LCBVbml2ZXJzaXR5IE1lZGljYWwgQ2Vu
dGVyIEdyb25pbmdlbiwgVW5pdmVyc2l0eSBvZiBHcm9uaW5nZW4sIFBPIEJveCAzMCAwMDEsIEhh
bnplcGxlaW4gMSwgOTcxMyBHWiBHcm9uaW5nZW4sIFRoZSBOZXRoZXJsYW5kcy4gZi5wLmouYnJv
dXdlcnNAdW1jZy5ubDwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkluY2lkZW5jZSBhbmQg
ZXBpZGVtaW9sb2d5IG9mIG5ldyBvbnNldCBoZWFydCBmYWlsdXJlIHdpdGggcHJlc2VydmVkIHZz
LiByZWR1Y2VkIGVqZWN0aW9uIGZyYWN0aW9uIGluIGEgY29tbXVuaXR5LWJhc2VkIGNvaG9ydDog
MTEteWVhciBmb2xsb3ctdXAgb2YgUFJFVkVORDwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5FdXIg
SGVhcnQgSjwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxl
PkV1ciBIZWFydCBKPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MTQyNC0zMTwvcGFn
ZXM+PHZvbHVtZT4zNDwvdm9sdW1lPjxudW1iZXI+MTk8L251bWJlcj48a2V5d29yZHM+PGtleXdv
cmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QWdlIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+
QWdlZDwva2V5d29yZD48a2V5d29yZD5CaW9tYXJrZXJzL21ldGFib2xpc208L2tleXdvcmQ+PGtl
eXdvcmQ+RXBpZGVtaW9sb2dpYyBNZXRob2RzPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5
d29yZD48a2V5d29yZD5IZWFydCBGYWlsdXJlLyplcGlkZW1pb2xvZ3kvcGh5c2lvcGF0aG9sb2d5
PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3Jk
PjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPk9iZXNpdHkvY29tcGxpY2F0
aW9ucy9tb3J0YWxpdHk8L2tleXdvcmQ+PGtleXdvcmQ+U2V4IEZhY3RvcnM8L2tleXdvcmQ+PGtl
eXdvcmQ+U3Ryb2tlIFZvbHVtZS9waHlzaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPlRpbWUtdG8t
VHJlYXRtZW50PC9rZXl3b3JkPjxrZXl3b3JkPkVwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29y
ZD5IRnBFRjwva2V5d29yZD48a2V5d29yZD5IRnJFRjwva2V5d29yZD48a2V5d29yZD5OZXcgb25z
ZXQgaGVhcnQgZmFpbHVyZTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEzPC95
ZWFyPjxwdWItZGF0ZXM+PGRhdGU+TWF5PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+
MTUyMi05NjQ1IChFbGVjdHJvbmljKSYjeEQ7MDE5NS02NjhYIChMaW5raW5nKTwvaXNibj48YWNj
ZXNzaW9uLW51bT4yMzQ3MDQ5NTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1
cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yMzQ3MDQ5NTwvdXJsPjwvcmVs
YXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTA5My9ldXJoZWFy
dGovZWh0MDY2PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmRO
b3RlPgB=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ccm91d2VyczwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+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ADDIN EN.CITE.DATA 12. Diabetic HFPEF patients have a significantly higher rate of hospitalisation and a reduced exercise capacityPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MaW5kbWFuPC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48
UmVjTnVtPjgxPC9SZWNOdW0+PERpc3BsYXlUZXh0PjxzdHlsZSBmYWNlPSJzdXBlcnNjcmlwdCI+
MTM8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj44MTwvcmVjLW51bWJl
cj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9Inp4dzkyd3MwczJ0YXptZXdwemR4
NWZ6bjVlMmQ5d2R3dnN2eiIgdGltZXN0YW1wPSIxNDgwMzg2NDkxIj44MTwva2V5PjwvZm9yZWln
bi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29u
dHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TGluZG1hbiwgQi4gUi48L2F1dGhvcj48YXV0aG9y
PkRhdmlsYS1Sb21hbiwgVi4gRy48L2F1dGhvcj48YXV0aG9yPk1hbm4sIEQuIEwuPC9hdXRob3I+
PGF1dGhvcj5NY051bHR5LCBTLjwvYXV0aG9yPjxhdXRob3I+U2VtaWdyYW4sIE0uIEouPC9hdXRo
b3I+PGF1dGhvcj5MZXdpcywgRy4gRC48L2F1dGhvcj48YXV0aG9yPmRlIGxhcyBGdWVudGVzLCBM
LjwvYXV0aG9yPjxhdXRob3I+Sm9zZXBoLCBTLiBNLjwvYXV0aG9yPjxhdXRob3I+VmFkZXIsIEou
PC9hdXRob3I+PGF1dGhvcj5IZXJuYW5kZXosIEEuIEYuPC9hdXRob3I+PGF1dGhvcj5SZWRmaWVs
ZCwgTS4gTS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5X
YXNoaW5ndG9uIFVuaXZlcnNpdHkgU2Nob29sIG9mIE1lZGljaW5lLCBTdC4gTG91aXMsIE1pc3Nv
dXJpLiBFbGVjdHJvbmljIGFkZHJlc3M6IGJsaW5kbWFuQGRvbS53dXN0bC5lZHUuJiN4RDtXYXNo
aW5ndG9uIFVuaXZlcnNpdHkgU2Nob29sIG9mIE1lZGljaW5lLCBTdC4gTG91aXMsIE1pc3NvdXJp
LiYjeEQ7RHVrZSBVbml2ZXJzaXR5IFNjaG9vbCBvZiBNZWRpY2luZSwgRHVyaGFtLCBOb3J0aCBD
YXJvbGluYS4mI3hEO0hhcnZhcmQgVW5pdmVyc2l0eSBTY2hvb2wgb2YgTWVkaWNpbmUsIEJvc3Rv
biwgTWFzc2FjaHVzZXR0cy4mI3hEO01heW8gQ2xpbmljLCBSb2NoZXN0ZXIsIE1pbm5lc290YS48
L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5DYXJkaW92YXNjdWxhciBwaGVub3R5cGUgaW4g
SEZwRUYgcGF0aWVudHMgd2l0aCBvciB3aXRob3V0IGRpYWJldGVzOiBhIFJFTEFYIHRyaWFsIGFu
Y2lsbGFyeSBzdHVkeTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5KIEFtIENvbGwgQ2FyZGlvbDwv
c2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkogQW0gQ29s
bCBDYXJkaW9sPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NTQxLTk8L3BhZ2VzPjx2
b2x1bWU+NjQ8L3ZvbHVtZT48bnVtYmVyPjY8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWdl
ZDwva2V5d29yZD48a2V5d29yZD5Db2hvcnQgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5EaWFi
ZXRlcyBNZWxsaXR1cy8qZGlhZ25vc2lzL2RydWcgdGhlcmFweS9lcGlkZW1pb2xvZ3k8L2tleXdv
cmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkhlYXJ0IEZhaWx1cmUvZGlhZ25v
c2lzL2RydWcgdGhlcmFweS8qZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwv
a2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3
b3JkPjxrZXl3b3JkPipQaGVub3R5cGU8L2tleXdvcmQ+PGtleXdvcmQ+UGhvc3Bob2RpZXN0ZXJh
c2UgNSBJbmhpYml0b3JzL3BoYXJtYWNvbG9neS8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxr
ZXl3b3JkPlBpcGVyYXppbmVzL3BoYXJtYWNvbG9neS90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+
PGtleXdvcmQ+UHJvc3BlY3RpdmUgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5QdXJpbmVzL3Bo
YXJtYWNvbG9neS90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+U2lsZGVuYWZpbCBD
aXRyYXRlPC9rZXl3b3JkPjxrZXl3b3JkPlN0cm9rZSBWb2x1bWUvZHJ1ZyBlZmZlY3RzLypwaHlz
aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPlN1bGZvbmVzL3BoYXJtYWNvbG9neS90aGVyYXBldXRp
YyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+YmlvbWFya2Vyczwva2V5d29yZD48a2V5d29yZD5kaWFi
ZXRlcyBtZWxsaXR1czwva2V5d29yZD48a2V5d29yZD5leGVyY2lzZSBjYXBhY2l0eTwva2V5d29y
ZD48a2V5d29yZD5oZWFydCBmYWlsdXJlIHdpdGggcHJlc2VydmVkIGVqZWN0aW9uIGZyYWN0aW9u
PC9rZXl3b3JkPjxrZXl3b3JkPmxlZnQgdmVudHJpY3VsYXIgc3RydWN0dXJlPC9rZXl3b3JkPjwv
a2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BdWcgMTI8
L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTU4LTM1OTcgKEVsZWN0cm9uaWMpJiN4
RDswNzM1LTEwOTcgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI1MTA0NTIxPC9hY2Nl
c3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5p
aC5nb3YvcHVibWVkLzI1MTA0NTIxPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20y
PlBNQzQxMzMxNDU8L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMTYvai5q
YWNjLjIwMTQuMDUuMDMwPC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+
PC9FbmROb3RlPn==
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MaW5kbWFuPC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48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ADDIN EN.CITE.DATA 13. Atrial fibrillation is common in this group, making up of a quarter of the population, and is associated with the same risk of stroke as those with a reduced ejection fractionADDIN CSL_CITATION { "citationItems" : [ { "id" : "ITEM-1", "itemData" : { "DOI" : "10.1161/CIRCHEARTFAILURE.114.001523", "ISSN" : "1941-3289", "author" : [ { "dropping-particle" : "", "family" : "Oluleye", "given" : "O. W.", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Rector", "given" : "T. S.", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Win", "given" : "S.", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "V.", "family" : "McMurray", "given" : "J. J.", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Zile", "given" : "M. R.", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Komajda", "given" : "M.", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "McKelvie", "given" : "R. S.", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Massie", "given" : "B.", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Carson", "given" : "P. E.", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" }, { "dropping-particle" : "", "family" : "Anand", "given" : "I. S.", "non-dropping-particle" : "", "parse-names" : false, "suffix" : "" } ], "container-title" : "Circulation: Heart Failure", "id" : "ITEM-1", "issue" : "6", "issued" : { "date-parts" : [ [ "2014" ] ] }, "page" : "960-966", "title" : "History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction", "type" : "article-journal", "volume" : "7" }, "uris" : [ "" ] } ], "mendeley" : { "formattedCitation" : "<sup>13</sup>", "plainTextFormattedCitation" : "13", "previouslyFormattedCitation" : "<sup>13</sup>" }, "properties" : { "noteIndex" : 0 }, "schema" : "" }13.HFpEF ManagementSimilar to patients with HFREF, the objectives of HF treatment in general are to improve quality of life, reduce hospitalisation, to reduce mortality and given the linkage between cardiac structure and the clinical phenotype to reverse cardiac remodelling. To date, clinical trials in HFPEF have largely been disappointing perhaps reflecting variability in trial designPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DbGVsYW5kPC9BdXRob3I+PFllYXI+MjAwNjwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DbGVsYW5kPC9BdXRob3I+PFllYXI+MjAwNjwvWWVhcj48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ADDIN EN.CITE.DATA 14-19, relatively limited study duration in comparison to the likely duration required for the development of HFPEF and the possibility that the disease mechanisms are not yet fully understood. The main principles of the management of HFPEF are to maintain strict control of blood pressure, relieve congestion, prevent ischemia, treat co-morbid conditions, and maintain atrial function through rate or rhythm control. As in patients with HFREF, the appropriate use of diuretics in the setting of volume overload in individuals with HFPEF is an important key to symptom relief. Avoidance of over-diuresis is important given the frequent co-existence of renal impairment together with the fact that HFPEF patients typically have a reduced stroke-volume and may be particularly sensitive to excessive reductions in pre-load. Building upon the very strong evidence base for ACE inhibitors and ARBs in HFREF, several large scale trials of these agents were conducted in HFPEFPEVuZE5vdGU+PENpdGU+PFllYXI+QXByaWwgMjAwNzwvWWVhcj48UmVjTnVtPjExMDwvUmVjTnVt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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PFllYXI+QXByaWwgMjAwNzwvWWVhcj48UmVjTnVtPjExMDwvUmVjTnVt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ADDIN EN.CITE.DATA 14, 20, 21 using drugs including perindopril, irbesartan and candesartan. Whilst trials failed in their primary endpoints, there was evidence of a modest reduction in hospitalisation for both ARBs and ACE inhibitors. Although detailed studies of the activity of the sympathetic nervous system in HFPEF have not been conducted, it has been postulated that beta blockers could be useful in HFPEF by extending diastolic filling time and reducing ischemia. Some patients with HFPEF have evidence of chronotropic incompetencePEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Cb3JsYXVnPC9BdXRob3I+PFllYXI+MjAwNjwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Cb3JsYXVnPC9BdXRob3I+PFllYXI+MjAwNjwvWWVhcj48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ADDIN EN.CITE.DATA 22, and trials assessing both nebivolol ADDIN EN.CITE <EndNote><Cite><Author>Jaski</Author><Year>1985</Year><RecNum>28</RecNum><DisplayText><style face="superscript">23</style></DisplayText><record><rec-number>28</rec-number><foreign-keys><key app="EN" db-id="zxw92ws0s2tazmewpzdx5fzn5e2d9wdwvsvz" timestamp="1480382089">28</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Jaski, B. E.</author><author>Fifer, M. A.</author><author>Wright, R. F.</author><author>Braunwald, E.</author><author>Colucci, W. S.</author></authors></contributors><titles><title>Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside</title><secondary-title>J Clin Invest</secondary-title></titles><periodical><full-title>J Clin Invest</full-title></periodical><pages>643-9</pages><volume>75</volume><number>2</number><keywords><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Cardiotonic Agents/*administration & dosage</keyword><keyword>Dose-Response Relationship, Drug</keyword><keyword>Female</keyword><keyword>Heart Failure/*drug therapy/physiopathology</keyword><keyword>Hemodynamics/drug effects</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Milrinone</keyword><keyword>Nitroprusside/administration & dosage</keyword><keyword>Pyridones/*administration & dosage</keyword><keyword>Vasodilator Agents/*administration & dosage</keyword></keywords><dates><year>1985</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>0021-9738 (Print)
0021-9738 (Linking)</isbn><accession-num>3973022</accession-num><urls><related-urls><url> and carvedilol ADDIN EN.CITE <EndNote><Cite><Author>Kubo</Author><Year>1985</Year><RecNum>29</RecNum><DisplayText><style face="superscript">24</style></DisplayText><record><rec-number>29</rec-number><foreign-keys><key app="EN" db-id="zxw92ws0s2tazmewpzdx5fzn5e2d9wdwvsvz" timestamp="1480382156">29</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kubo, S. H.</author><author>Cody, R. J.</author><author>Chatterjee, K.</author><author>Simonton, C.</author><author>Rutman, H.</author><author>Leonard, D.</author></authors></contributors><titles><title>Acute dose range study of milrinone in congestive heart failure</title><secondary-title>Am J Cardiol</secondary-title></titles><periodical><full-title>Am J Cardiol</full-title></periodical><pages>726-30</pages><volume>55</volume><number>6</number><keywords><keyword>Administration, Oral</keyword><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Cardiotonic Agents/*therapeutic use</keyword><keyword>Chronic Disease</keyword><keyword>Dose-Response Relationship, Drug</keyword><keyword>Female</keyword><keyword>Heart Failure/*drug therapy/physiopathology</keyword><keyword>Hemodynamics/drug effects</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Milrinone</keyword><keyword>Pyridones/*administration & dosage/pharmacology</keyword><keyword>Time Factors</keyword></keywords><dates><year>1985</year><pub-dates><date>Mar 1</date></pub-dates></dates><isbn>0002-9149 (Print)
0002-9149 (Linking)</isbn><accession-num>3976517</accession-num><urls><related-urls><url> in this respect have been negative. Short term use of ivabradine has been shown to improve exercise capacity ADDIN EN.CITE <EndNote><Cite><Author>Edelson</Author><Year>1986</Year><RecNum>30</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>30</rec-number><foreign-keys><key app="EN" db-id="zxw92ws0s2tazmewpzdx5fzn5e2d9wdwvsvz" timestamp="1480382199">30</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Edelson, J.</author><author>Stroshane, R.</author><author>Benziger, D. P.</author><author>Cody, R.</author><author>Benotti, J.</author><author>Hood, W. B., Jr.</author><author>Chatterjee, K.</author><author>Luczkowec, C.</author><author>Krebs, C.</author><author>Schwartz, R.</author></authors></contributors><titles><title>Pharmacokinetics of the bipyridines amrinone and milrinone</title><secondary-title>Circulation</secondary-title></titles><periodical><full-title>Circulation</full-title></periodical><pages>III145-52</pages><volume>73</volume><number>3 Pt 2</number><keywords><keyword>Administration, Oral</keyword><keyword>Aminopyridines/administration & dosage/*metabolism/therapeutic use</keyword><keyword>Amrinone</keyword><keyword>Clinical Trials as Topic</keyword><keyword>Half-Life</keyword><keyword>Heart Failure/*drug therapy</keyword><keyword>Humans</keyword><keyword>Infusions, Parenteral</keyword><keyword>Kinetics</keyword><keyword>Male</keyword><keyword>Milrinone</keyword><keyword>Pyridones/administration & dosage/*metabolism/therapeutic use</keyword><keyword>Random Allocation</keyword><keyword>Time Factors</keyword></keywords><dates><year>1986</year><pub-dates><date>Mar</date></pub-dates></dates><isbn>0009-7322 (Print)
0009-7322 (Linking)</isbn><accession-num>3510771</accession-num><urls><related-urls><url>, and larger studies are under way. In patients with atrial fibrillation, control of the ventricular rate is paramountPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NY011cnJheTwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NY011cnJheTwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+
PFJlY051bT43NzwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQi
Pjg8L3N0eWxlPjwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj43NzwvcmVjLW51bWJl
cj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9Inp4dzkyd3MwczJ0YXptZXdwemR4
NWZ6bjVlMmQ5d2R3dnN2eiIgdGltZXN0YW1wPSIxNDgwMzg2MjE3Ij43Nzwva2V5PjwvZm9yZWln
bi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29u
dHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+TWNNdXJyYXksIEouIEouPC9hdXRob3I+PGF1dGhv
cj5BZGFtb3BvdWxvcywgUy48L2F1dGhvcj48YXV0aG9yPkFua2VyLCBTLiBELjwvYXV0aG9yPjxh
dXRob3I+QXVyaWNjaGlvLCBBLjwvYXV0aG9yPjxhdXRob3I+Qm9obSwgTS48L2F1dGhvcj48YXV0
aG9yPkRpY2tzdGVpbiwgSy48L2F1dGhvcj48YXV0aG9yPkZhbGssIFYuPC9hdXRob3I+PGF1dGhv
cj5GaWxpcHBhdG9zLCBHLjwvYXV0aG9yPjxhdXRob3I+Rm9uc2VjYSwgQy48L2F1dGhvcj48YXV0
aG9yPkdvbWV6LVNhbmNoZXosIE0uIEEuPC9hdXRob3I+PGF1dGhvcj5KYWFyc21hLCBULjwvYXV0
aG9yPjxhdXRob3I+S29iZXIsIEwuPC9hdXRob3I+PGF1dGhvcj5MaXAsIEcuIFkuPC9hdXRob3I+
PGF1dGhvcj5NYWdnaW9uaSwgQS4gUC48L2F1dGhvcj48YXV0aG9yPlBhcmtob21lbmtvLCBBLjwv
YXV0aG9yPjxhdXRob3I+UGllc2tlLCBCLiBNLjwvYXV0aG9yPjxhdXRob3I+UG9wZXNjdSwgQi4g
QS48L2F1dGhvcj48YXV0aG9yPlJvbm5ldmlrLCBQLiBLLjwvYXV0aG9yPjxhdXRob3I+UnV0dGVu
LCBGLiBILjwvYXV0aG9yPjxhdXRob3I+U2Nod2l0dGVyLCBKLjwvYXV0aG9yPjxhdXRob3I+U2Vm
ZXJvdmljLCBQLjwvYXV0aG9yPjxhdXRob3I+U3RlcGluc2thLCBKLjwvYXV0aG9yPjxhdXRob3I+
VHJpbmRhZGUsIFAuIFQuPC9hdXRob3I+PGF1dGhvcj5Wb29ycywgQS4gQS48L2F1dGhvcj48YXV0
aG9yPlphbm5hZCwgRi48L2F1dGhvcj48YXV0aG9yPlplaWhlciwgQS48L2F1dGhvcj48YXV0aG9y
PlRhc2sgRm9yY2UgZm9yIHRoZSwgRGlhZ25vc2lzPC9hdXRob3I+PGF1dGhvcj5UcmVhdG1lbnQg
b2YsIEFjdXRlPC9hdXRob3I+PGF1dGhvcj5DaHJvbmljIEhlYXJ0IEZhaWx1cmUgb2YgdGhlIEV1
cm9wZWFuIFNvY2lldHkgb2YsIENhcmRpb2xvZ3k8L2F1dGhvcj48YXV0aG9yPkJheCwgSi4gSi48
L2F1dGhvcj48YXV0aG9yPkJhdW1nYXJ0bmVyLCBILjwvYXV0aG9yPjxhdXRob3I+Q2Vjb25pLCBD
LjwvYXV0aG9yPjxhdXRob3I+RGVhbiwgVi48L2F1dGhvcj48YXV0aG9yPkRlYXRvbiwgQy48L2F1
dGhvcj48YXV0aG9yPkZhZ2FyZCwgUi48L2F1dGhvcj48YXV0aG9yPkZ1bmNrLUJyZW50YW5vLCBD
LjwvYXV0aG9yPjxhdXRob3I+SGFzZGFpLCBELjwvYXV0aG9yPjxhdXRob3I+SG9lcywgQS48L2F1
dGhvcj48YXV0aG9yPktpcmNoaG9mLCBQLjwvYXV0aG9yPjxhdXRob3I+S251dXRpLCBKLjwvYXV0
aG9yPjxhdXRob3I+S29saCwgUC48L2F1dGhvcj48YXV0aG9yPk1jRG9uYWdoLCBULjwvYXV0aG9y
PjxhdXRob3I+TW91bGluLCBDLjwvYXV0aG9yPjxhdXRob3I+UG9wZXNjdSwgQi4gQS48L2F1dGhv
cj48YXV0aG9yPlJlaW5lciwgWi48L2F1dGhvcj48YXV0aG9yPlNlY2h0ZW0sIFUuPC9hdXRob3I+
PGF1dGhvcj5TaXJuZXMsIFAuIEEuPC9hdXRob3I+PGF1dGhvcj5UZW5kZXJhLCBNLjwvYXV0aG9y
PjxhdXRob3I+VG9yYmlja2ksIEEuPC9hdXRob3I+PGF1dGhvcj5WYWhhbmlhbiwgQS48L2F1dGhv
cj48YXV0aG9yPldpbmRlY2tlciwgUy48L2F1dGhvcj48YXV0aG9yPk1jRG9uYWdoLCBULjwvYXV0
aG9yPjxhdXRob3I+U2VjaHRlbSwgVS48L2F1dGhvcj48YXV0aG9yPkJvbmV0LCBMLiBBLjwvYXV0
aG9yPjxhdXRob3I+QXZyYWFtaWRlcywgUC48L2F1dGhvcj48YXV0aG9yPkJlbiBMYW1pbiwgSC4g
QS48L2F1dGhvcj48YXV0aG9yPkJyaWdub2xlLCBNLjwvYXV0aG9yPjxhdXRob3I+Q29jYSwgQS48
L2F1dGhvcj48YXV0aG9yPkNvd2J1cm4sIFAuPC9hdXRob3I+PGF1dGhvcj5EYXJnaWUsIEguPC9h
dXRob3I+PGF1dGhvcj5FbGxpb3R0LCBQLjwvYXV0aG9yPjxhdXRob3I+RmxhY2hza2FtcGYsIEYu
IEEuPC9hdXRob3I+PGF1dGhvcj5HdWlkYSwgRy4gRi48L2F1dGhvcj48YXV0aG9yPkhhcmRtYW4s
IFMuPC9hdXRob3I+PGF1dGhvcj5JdW5nLCBCLjwvYXV0aG9yPjxhdXRob3I+TWVya2VseSwgQi48
L2F1dGhvcj48YXV0aG9yPk11ZWxsZXIsIEMuPC9hdXRob3I+PGF1dGhvcj5OYW5hcywgSi4gTi48
L2F1dGhvcj48YXV0aG9yPk5pZWxzZW4sIE8uIFcuPC9hdXRob3I+PGF1dGhvcj5Pcm4sIFMuPC9h
dXRob3I+PGF1dGhvcj5QYXJpc3NpcywgSi4gVC48L2F1dGhvcj48YXV0aG9yPlBvbmlrb3dza2ks
IFAuPC9hdXRob3I+PGF1dGhvcj5FLiBTLiBDLiBDb21taXR0ZWUgZm9yIFByYWN0aWNlIEd1aWRl
bGluZXM8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5HbGFz
Z293IEcxMiA4UVEsIFVLLiBqb2huLm1jbXVycmF5QGdsYXNnb3cuYWMudWs8L2F1dGgtYWRkcmVz
cz48dGl0bGVzPjx0aXRsZT5FU0MgZ3VpZGVsaW5lcyBmb3IgdGhlIGRpYWdub3NpcyBhbmQgdHJl
YXRtZW50IG9mIGFjdXRlIGFuZCBjaHJvbmljIGhlYXJ0IGZhaWx1cmUgMjAxMjogVGhlIFRhc2sg
Rm9yY2UgZm9yIHRoZSBEaWFnbm9zaXMgYW5kIFRyZWF0bWVudCBvZiBBY3V0ZSBhbmQgQ2hyb25p
YyBIZWFydCBGYWlsdXJlIDIwMTIgb2YgdGhlIEV1cm9wZWFuIFNvY2lldHkgb2YgQ2FyZGlvbG9n
eS4gRGV2ZWxvcGVkIGluIGNvbGxhYm9yYXRpb24gd2l0aCB0aGUgSGVhcnQgRmFpbHVyZSBBc3Nv
Y2lhdGlvbiAoSEZBKSBvZiB0aGUgRVNDPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkV1ciBKIEhl
YXJ0IEZhaWw8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs
ZT5FdXIgSiBIZWFydCBGYWlsPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+ODAzLTY5
PC9wYWdlcz48dm9sdW1lPjE0PC92b2x1bWU+PG51bWJlcj44PC9udW1iZXI+PGtleXdvcmRzPjxr
ZXl3b3JkPkFsZ29yaXRobXM8L2tleXdvcmQ+PGtleXdvcmQ+QW50aWh5cGVydGVuc2l2ZSBBZ2Vu
dHMvdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPkNhcmRpb3RvbmljIEFnZW50cy90
aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+RXVyb3BlPC9rZXl3b3JkPjxrZXl3b3Jk
PkhlYXJ0IEZhaWx1cmUvZGlhZ25vc2lzLypkcnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+
SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPk5hdHJpdXJldGljIFBlcHRpZGVzPC9rZXl3b3JkPjxr
ZXl3b3JkPlJlbmluLUFuZ2lvdGVuc2luIFN5c3RlbTwva2V5d29yZD48a2V5d29yZD5Tb2NpZXRp
ZXMsIE1lZGljYWw8L2tleXdvcmQ+PGtleXdvcmQ+U3Ryb2tlIFZvbHVtZTwva2V5d29yZD48a2V5
d29yZD5WZW50cmljdWxhciBGdW5jdGlvbiwgTGVmdDwva2V5d29yZD48L2tleXdvcmRzPjxkYXRl
cz48eWVhcj4yMDEyPC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+QXVnPC9kYXRlPjwvcHViLWRhdGVz
PjwvZGF0ZXM+PGlzYm4+MTg3OS0wODQ0IChFbGVjdHJvbmljKSYjeEQ7MTM4OC05ODQyIChMaW5r
aW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yMjgyODcxMjwvYWNjZXNzaW9uLW51bT48dXJscz48
cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yMjgy
ODcxMjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+
MTAuMTA5My9ldXJqaGYvaGZzMTA1PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48
L0NpdGU+PC9FbmROb3RlPn==
ADDIN EN.CITE.DATA 8. Based upon the hypothesis that activation of the renin-angiotensin-aldosterone system is important in the pathogenesis of HFPEF, studies have been conducted into the utility of spironolactone. In the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study ADDIN EN.CITE <EndNote><Cite><Author>Seino</Author><Year>1995</Year><RecNum>31</RecNum><DisplayText><style face="superscript">26</style></DisplayText><record><rec-number>31</rec-number><foreign-keys><key app="EN" db-id="zxw92ws0s2tazmewpzdx5fzn5e2d9wdwvsvz" timestamp="1480382232">31</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Seino, Y.</author><author>Takano, T.</author><author>Hayakawa, H.</author><author>Kanmatsuse, K.</author><author>Saitoh, S.</author><author>Saitoh, T.</author><author>Kamishima, G.</author><author>Watanabe, K.</author><author>Motomiya, T.</author><author>Murata, M.</author><author>et al.,</author></authors></contributors><auth-address>Nippon Medical School Hospital, Japan.</auth-address><titles><title>Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure</title><secondary-title>Cardiology</secondary-title></titles><periodical><full-title>Cardiology</full-title></periodical><pages>34-40</pages><volume>86</volume><number>1</number><keywords><keyword>Acute Disease</keyword><keyword>Administration, Oral</keyword><keyword>Aged</keyword><keyword>Female</keyword><keyword>Heart Failure/*drug therapy/metabolism/physiopathology</keyword><keyword>Hemodynamics/*drug effects</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Milrinone</keyword><keyword>Prospective Studies</keyword><keyword>Pyridones/*pharmacokinetics/therapeutic use</keyword></keywords><dates><year>1995</year></dates><isbn>0008-6312 (Print)
0008-6312 (Linking)</isbn><accession-num>7728786</accession-num><urls><related-urls><url> there was evidence of improved diastolic function however with no other signal of benefit. In the larger TOPCAT outcome study, spironolactone treatment was not associated with improved survival, although there was evidence of a modest reduction in HF hospitalisationPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QaXR0PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVj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=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QaXR0PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVj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=
ADDIN EN.CITE.DATA 16. Importantly in both studies blood pressure was also lowered.Rationale for Performing the Study:Kaye previously tested the hypothesis that milrinone may be beneficial in HFpEF30 .This concept was based on the properties of milrinone, a phosphodiesterase type III inhibitor. The drug exhibits several pharmacological actions that may be favorable in HFPEF. These include beneficial effects on left ventricular diastolic function, pulmonary vasodilation and systemic vasodilation when investigated in the setting of reduced ventricular function. Milrinone exhibits positive inotropic actions which may also potentially offer some value in HFPEF, given it has been demonstrated that some aspects of LV systolic function are reduced in HFPEF. In the study performed by Kaye, the effects of a single dose of milrinone, 50ug/kg, were investigated on rest and exercise hemodynamics. The study showed the drug significantly reduced rest and exercise pulmonary capillary wedge pressures30 .Within this context, this study aims to examine the effects a lowdoseof intra-venous (iv) milrinone to determine the concentration/dose vs hemodynamic profile. Study ObjectivesObjectivesThe primary objective of the study is to:To determine the effectiveness of a low dose of iv milrinone on exercise hemodynamics in HFpEF patients. Study DescriptionThis is a phase 1b, randomized placebo controlled Investigator led study to assess the dose response of a low dose (25ug/kg) of iv milrinone or placebo in 8 subjects with HFpEF. After Screening, eligible subjects will return for the study day during which they will undergo a right heart catheterization study while receiving a specified dose of iv milrinone or placebo. Study PopulationThe study population will include patients with heart failure with preserved ejection fraction (HFpEF), recruited from stable outpatients. Selection CriteriaInclusion CriteriaPatients are enrolled only if they met the following criteria. Males and females aged 18-85. Symptoms of heart failure (NYHA class III or ambulatory class IV). Left Ventricular Ejection Fraction (LVEF) ≥50%.Heart Failure hospitalization within 12 months or NT-proBNP >125 pg/mL. Evidence of prior diagnosis of HFpEF, confirmed via: Echocardiographic parameters (one or more of the following) observed//recorded in previous 6 months:septal E/e’ ≥ 13 (a measure of LV filling pressure) orleft atrial volume index > 34ml/m2 or LV mass index ≥ 115 g/m2 (male) or ≥ 95 g/m2 (female). orHemodynamic exercise test within 6 months. Stable medical heart failure therapy including diuretics for 2 weeks.Able to give written informed consent and agree to adhere to all protocol requirements. Potassium between 4 – 5.5 mmol/LExclusion Criteria:Myocardial infarction or acute coronary syndromes within 90 days. Hypotension (systolic BP <90 mmHg) at Screening or BaselineSevere Hypertension (systolic BP >180 mmHg) at Screening or BaselinePoorly controlled atrial fibrillation (ventricular rate>120bpm).History of significant ventricular arrhythmia in the past yearSignificant renal impairment (eGFR <30 ml/min/1.73 m2)Severe physical limitation defined by inability to complete a minimum exercise tolerance time of 120 seconds on two treadmill tests within 2 weeks of enrollmentRestrictive or infiltrative cardiomyopathy.PregnancyHistory of allergic reaction to milrinone or any excipients in the study drug. Participation in another clinical trialPrior and Concomitant Therapies MedicationsAll concomitant therapies taken within 7 days of screening up until the closeout visit will be captured in the source documents and CRF. All patients are required to be on optimal medical therapy for heart failure as determined by their managing cardiologist.The following medications are prohibited from 7 days prior to screening through to the end of treatment:Intravenous inotropes (milrinone, dobutamine, epinephrine, levosimendan), cilostazolInvestigational ProductDescriptionThe product investigated is the approved product, iv milrinone (Primacor?, Appendix 1). .Packaging and LabelingThe study drug is provided in glass ampoules for dilution in 0.9% NaCl. Ampoules are labeled according to relevant guidelines and legislation.Storage, Dispensing and Reconciliation of Study DrugMilrinone will be dispensed blinded via The Alfred Clinical Trialsl Pharmacy. Randomisation log/envelope to be kept by pharmacy. Investigational product should be stored at 25oC or below. Do not freeze. Temperature excursions up to 30oC are permitted.The Principal Investigator is responsible for drug product accountability, reconciliation, and record maintenance. The Principal Investigator or designated site staff must maintain drug product accountability records throughout the course of the study including records for the amount of investigational product received, the identification of the subject for whom the drug was dispensed, the date(s) and the quantity of the drug dispensed and any amount returned.Study EndpointsExploratoryChanges compared to baseline in:Pulmonary capillary wedge pressurePulmonary artery pressures (mean, systolic, diastolic and pulse pressure) and derived parameters including pulmonary arterial compliance and elastanceTotal (thermodilution) cardiac outputSystemic blood pressure (measured non-invasively)Peripheral vascular resistanceBlood pressure and heart rateCardiac index.Blood pressure (mean and systolic, where appropriate)Plasma milrinone levelsPrimary (safety)All adverse event (AE) recording and assessments.Study ProceduresTable 2 outlines the study procedures to be completed. Table SEQ Table \* ARABIC 2: Study Procedures.VisitPre-screeningStudy day2Timing/windowDay -28 to 1Day 1Informed consentXInclusion/Exclusion criteriaDemographicsXMedical/medication historyXXphysical examXXVital signsXXNYHA ClassXXHaematologyXBiochemistry, EUC, LFTXXBNP and NT proBNPXXTroponinXX12 Lead ECGXXRest and Exercise Hemodynamic evaluationXPlasma milrinone levelsXAdverse event monitoringXConcomitant medicationsXX1 To be taken at the end of infusion, and at the end of exercise test. 2 plasma levels will need to be taken2 A focused cardiovascular exam will be conducted at the study visit by the PI or a designated specialist heart failure/LVAD cardiologist at day 1.Exploratory EndpointsHemodynamic Evaluation: Subjects will undergo right heart catheterisation via the cubital vein or internal jugular vein according to local clinical practice at baseline and follow up visits. Right atrial, right ventricular and pulmonary artery and wedge pressures will be measured at gentle held expiration. Thermodilution cardiac output measurement will be performed in triplicate. Following baseline measures, subjects will supine perform symptom-limited supine cycling at incremental levels of 20 Watts for 3 minutes (exercise will not be performed if the resting RHC unexpectedly demonstrates severe pulmonary hypertension PA systolic>60mmHg). The test will be stopped when the patient experiences limiting dyspnoea or other limiting symptoms. Measures will be obtained at rest, 20W and peak exercise.Following initial rest and exercise evaluation, patients will be randomly allocated to receive either a standard loading dose of milrinone (25 ug/kg) over 10 min or placebo. Neither the patient nor the investigator will know which group the subject has been allocated to. Rest and exercise hemodynamic (as above) will be repeated after a further 10 minutes. At the designated time point (after 20 minute infusion), blood will be drawn (2 samples) for the measurement of plasma milrinone levels. Blood samples will be collected and stored according to the Study Reference Manual. CRD-102 levels (ng/mL) will be determined using liquid chromatography- tandem mass spectrometry (LC/MS/MS) by CPR Pharma Services Pty Ltd, Adelaide, Australia.Safety EndpointsSafety will be assessed by recording of AEs, vital signs, laboratory parameters, and physical/cardiovascular examinations.Each subject will undergo a complete medical history (including weight measurement) and physical exam prior to randomization to assess their clinical status and to confirm eligibility for study participation. Physical examinations during the study will include height (at Screening only) and weight, and assessment of skin, head, neck, lymphatic, eyes, ears, nose and throat, abdomen, and respiratory, cardiovascular/peripheral vascular, endocrine, central nervous, genitourinary and musculoskeletal systems as appropriate to determine general condition. New or worsening clinically significant abnormalities will be reported as an AE. Post Screening, a symptom-directed PE will be conducted if required, based on prior findings and symptoms.A focused cardiovascular exam will be conducted at the study visit by the PI or a designated specialist heart failure cardiologist. Subjects will undergo a 12-lead ecg at the study visit. Subjects will be questioned and monitored throughout the study with regard to any AEs they may have experienced. See Section 9 for further details on recording AEs.Blood samples will be taken for safety assessments. The following specific tests will be performed at the site’s local pathology laboratory:Haematology: Haemoglobin, haematocrit, red blood cell (RBC) count, white blood cell (WBC) count with differential, and platelet count.Serum Chemistry: Sodium, potassium, urea, gamma glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, lactate dehydrogenase (LDH), and creatinine (calculated creatinine clearance using the Cockcroft and Gault formula).Vital signs will be measured after the subject has been supine for 10 minutes and will include blood pressure (BP) on the same arm (if possible) throughout study, pulse rate, respiratory rate and temperature. Blood pressure will be measured in the semi-recumbent position, according to the preferred method by the Principal Investigator, optimized for each patient (ie Doppler, oximetry or automated oscillometry as appropriate). Blood pressure will be notated at the visit as mean or systolic according to the audible profile. Heart rate will be recorded over a 30 second period.Medical MonitoringThe Principal Investigator will designate a Medical Monitor for safety and clinical reporting. This Medical Monitor will review safety endpoints and subject data, and answer queries from both Investigators and study personnel. The Medical Monitor and the Principal Investigator will review data periodically from a 5 subject block. The Medical Monitor will provide regulatory oversight from a clinical perspective.Study VisitsThe study will be conducted over 1-day time period with 1 screening visit and 1 day-one visit. (Both screening and study visits can be performed on the same day if required). The study schedule is outlined in Table 1. Informed Consent ProcessThe Investigator must provide adequate information regarding the study conduct and obtain written informed consent from the subject before any tests or investigations outlined in the study protocol are carried out. Patients will be provided with a copy of the Participant Information and Consent Form (PICF) to read and discuss with family members, friends or family doctor. Any questions or concerns will be answered by the investigator administering the consent. Patients will be invited to participate if they demonstrate an understanding of what the study involves, the risks and the procedures involved. The PICF must be personally signed and dated by both the Investigator obtaining consent and the subject. The patient will be given a copy of the signed PICF. The original will be retained by the site.Screening Visit (Day -28 to Day 1)The purpose of the Screening visit is to confirm subject eligibility against inclusion and exclusion criteria. Screening assessments may be performed on different days within the Screening period, if required. Once written informed consent has been obtained, the following visit assessments and procedures will be performed;Review eligibility criteria.Record subject demographic data.Review and record medical and medication history, and current conditions and medications.Physical examination including height and weight (see Section 8.1).Vital signs (see Section 8.1).12 lead ECG Blood sample for BNP and NT proBNP testsSafety laboratory tests including haematology and biochemistryRe-ScreensOne repeat test of each individual screening assessment (e.g., laboratory tests, ECG) is allowed, within the screening period. Study Day (Day 1)Subjects will return to the site for hemodynamic evaluation. Review eligibility criteria.Review and record any new medical conditions since the Screening Visit as medical historyReview and record any changes to medicationsCardiovascular examination (see Section 8.1).Vital signs (see Section 8.1).12 lead ecg Record subject’s NYHA ClassSafety laboratory tests including haematology and biochemistry (see Section 8.1).Concomitant medication review.Hemodynamic exercise evaluationEarly termination visitNot applicable. Adverse EventsDefinitionsAn adverse event is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.? An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. MonitoringAdverse events will be collected and recorded in the CRF for subjects. Throughout the study, reported and observed AEs will be documented in the medical records and the CRF, along with their intensity, whether or not considered treatment-related. This will include any new signs, symptoms, injury or illness, including increased severity or frequency of previously existing signs, symptoms, injury, or illness.Conditions existing prior to screening will be recorded as part of the subject’s medical history.The investigator will be responsible for assessing the relationship of AEs to the study medication; relationship will be classified as not related, unlikely related, probably related, or definitely related. The Investigator will follow-up on all AEs until they resolve, become stable, or until they can be explained by another known cause(s) (i.e., concurrent condition or medication) and clinical judgment indicates that further evaluation is not warranted.? All findings relevant to the final outcome of an AE will be reported in the subject’s medical record. Intensity of Adverse EventsThe intensity (or severity) of AEs is characterized as mild, moderate, or severe: Mild:Causes no limitation of usual activities? Moderate:Causes some limitation of usual activities? Severe:Prevents or severely limits usual activities? Relationship to Study MedicationThe degree of “relatedness” of the AE to IV milrinone will be assigned by the PI using the following scale: Not related: AE for which there is evidence of another explanation, e.g. the adverse event is obviously explained by the subject’s disease(s), is in accordance with the known effect of a concomitant medication or has occurred prior to first administration of IV milrinone. Unlikely related: AE with a time to IV milrinone administration that makes a relationship improbable (but not impossible), and disease or other drugs provide plausible explanations Probably related: AE with reasonable time relationship to IV milrinone administration that is unlikely to be attributed to disease or other drugs. Response to IV milrinone withdrawal is clinically reasonable. Rechallenge is not required. Definitely related: AE with plausible time relationship to IV milrinone administration which cannot be explained by disease or other drugs. Response to IV Milrinone withdrawal is plausible (pharmacologically, pathologically), and event is definitive pharmacologically or phenomenologically (i.e. an objective and specific medical disorder or a recognised pharmacological phenomenon). Rechallenge, if performed/necessary, is satisfactory. Serious Adverse EventsA SAE is defined as an AE that: Results in death Is immediately life-threatening (there is an immediate risk of death from the AE as it occurred; this does not include an AE that had it occurred in a more serious form may have caused death) Results in or prolongs an in-patient hospitalization (Note: Hospitalisation is defined as in-patient admission or care regardless of duration.)Out-patient treatment in an emergency room is not in itself an SAE, although the reasons for it may be (e.g. bronchospasm, laryngeal oedema). Elective surgery, hospitalisation for social reasons (with no causal AE), or hospital admissions and/or surgical operations planned before or during this study are not considered AEs if the illness or disease existed before the subject was enrolled in the study, provided that it did not deteriorate in an unexpected way during the study.)? Results in persistent or significant disability (permanent or substantial disruption of one’s ability to conduct normal life functions)? Is a congenital anomaly/birth defect (in offspring of a subject using the study medication regardless of time to diagnosis) Is considered an important medical event Important medical events are defined as events that, based upon appropriate medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes defining an SAE. Examples of important medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in in-patient hospitalization, or the development of drug dependency or drug abuse. Reporting of Serious Adverse EventsInvestigators and other site personnel must report SAEs to The Alfred Hospital HREC or designee within 24 hours of becoming aware of the SAE, regardless of causality.Follow-up information on SAEs must also be reported by the investigational site within the same time frame. If a non-serious AE becomes serious, this and other relevant follow-up information must also be provided within 24 hours.Clinical Laboratory Abnormalities and Other Abnormal Assessments as AEs and SAEsAbnormal laboratory findings (e.g. clinical chemistry, hematologys) or other abnormal assessments (e.g. vital signs) that are judged by the investigator as clinically significant will be recorded as AEs or SAEs if they meet the definition of an AE, as defined in Section 7.2 or SAE as defined in Section 7.3. Clinically significant abnormal laboratory findings or other abnormal assessments that are detected during the study or are present at baseline and significantly worsen following the start of the study will be reported as AEs or SAEs. However, clinically significant abnormal laboratory findings or other abnormal assessments that are associated with a disease reported in the medical history, unless judged by the investigator as more severe than expected for the subject’s condition, or that are present or detected at the start of the study and do not worsen, will not be reported as AEs or SAEs.Statistical ConsiderationsSample size 8 patients at the dose level 25ug/kg/hr will be included in the trial. This will comprise of 6 patients receiving active (IV milrinone), and 2 patients being assigned to receiving placebo. Up to a maximum of 8 patients may be studied.Safety EvaluationsThe safety measurements evaluated will be clinical assessment of vital signs, physical examinations and cardiovascular examinations, MACCE, adverse (AE) and serious adverse event (SAE) monitoring throughout the protocol. In addition, laboratory safety assessments (haematology and biochemistry) will be conducted. All subjects who receive any amount of the drug product will be included in the Safety Population. Exploratory EvaluationsThe exploratory evaluations of the will be study will examine changes compared to baseline in: Pulmonary capillary wedge pressurePulmonary artery pressures (mean, systolic, diastolic and pulse pressure) and derived parameters including pulmonary arterial compliance and elastanceCardiac output (thermodilution)Systemic blood pressure (measured non-invasively)Peripheral vascular resistanceHeart rateBlood pressure (mean and systolic, where appropriate)Data ManagementA Case Report Form (CRF) will be completed by authorised study site personal designated by the investigator for each study subject summarising all study data. Subjects will only be referred to in the CRF by their subject number in order to retain subject confidentiality. The CRFs should always reflect the latest observations on the subjects participating in the trial; therefore, the CRFs are to be completed as soon as possible after the subject’s visit. The Investigator must verify that all data entries in the CRFs are accurate and correct. If some assessments are not done, or if certain information is not available or not applicable or unknown, this should be indicated in the CRF. The Investigator will be required to sign off on the clinical data.Source Data and Retention of RecordsSource documents are original documents, data, and records from which the subject’s CRF data are obtained. These include but are not limited to hospital records, clinical and office charts, laboratory and pharmacy records, and correspondence. In this study, CRFs may not be used as source documents.The Investigator is responsible for maintaining source documents. Data from this study may be shared with Cardiora Pty Ltd, a company that has interest in developing another form of milrinone for HFPEF subject to additional ethics review and approval at the time of sharing.Estimated Duration of the StudyIt is anticipated that this study will be conducted over a 6- month duration.Participant Information and Informed ConsentPrior to the commencement of any study specific procedure, participants are to be informed of the study, invited to participate, handed a written participant information sheet and consent form (PICF) and given the opportunity to discuss the study with family, friends, the participants General Practitioner (GP) and the study Principal Investigator (PI). The study participant will then be asked to sign the EC/IRB approved PICF, and a copy of the completed PICF given to the participant.References ADDIN EN.REFLIST 1.Note for Guidance on Good Clinical Practice (CPMP/GCP/135/95) and Note for Guidance on Good Clinical Practice (CPMP/GCP/135/95) annotated with Therapeutic Goods Administration (TGA) comments DSEB. July 2000.2.Mosterd A and Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137-46.3.McKee PA, Castelli WP, McNamara PM and Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-6.4.Aurigemma GP, Zile MR and Gaasch WH. Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation. 2006;113:296-304.5.Carabello BA. Evolution of the study of left ventricular function: everything old is new again. Circulation. 2002;105:2701-3.6.Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL and Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-9.7.Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology F and American Heart Association Task Force on Practice G. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-239.8.McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Task Force for the D, Treatment of A, Chronic Heart Failure of the European Society of C, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P and Guidelines ESCCfP. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803-69.9.Zile MR LW. Heart failure with preserved ejection fraction. In: D. L. Z. D. Mann, Libby P, Bonow R, ed. Braunwald's Heart Disease: Elsevier Inc; 2014(10th Edition): 557-574.10.Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA and Roger VL. Systolic and diastolic heart failure in the community. JAMA. 2006;296:2209-16.11.Borlaug BA. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. Circ J. 2014;78:20-32.12.Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ and van Gilst WH. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013;34:1424-31.13.Lindman BR, Davila-Roman VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF and Redfield MM. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64:541-9.14.Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J and Investigators P-C. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-45.15.McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P-H and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.16.Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM and Investigators T. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-92.17.Redfield MM, Borlaug BA, Lewis GD, Mohammed SF, Semigran MJ, Lewinter MM, Deswal A, Hernandez AF, Lee KL, Braunwald E and Heart Failure Clinical Research N. PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ Heart Fail. 2012;5:653-9.18.Shah RV, Desai AS and Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J Card Fail. 2010;16:260-7.19.Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC and Deo RC. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131:269-79.20.Primacor? (milrinone lactate injection; 200 mcg/mL in 5% dextrose injection) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC. . . April 2007.21.Baim DS, McDowell AV, Cherniles J, Monrad ES, Parker JA, Edelson J, Braunwald E and Grossman W. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure. N Engl J Med. 1983;309:748-56.22.Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC and Kass DA. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation. 2006;114:2138-47.23.Jaski BE, Fifer MA, Wright RF, Braunwald E and Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest. 1985;75:643-9.24.Kubo SH, Cody RJ, Chatterjee K, Simonton C, Rutman H and Leonard D. Acute dose range study of milrinone in congestive heart failure. Am J Cardiol. 1985;55:726-30.25.Edelson J, Stroshane R, Benziger DP, Cody R, Benotti J, Hood WB, Jr., Chatterjee K, Luczkowec C, Krebs C and Schwartz R. Pharmacokinetics of the bipyridines amrinone and milrinone. Circulation. 1986;73:III145-52.26.Seino Y, Takano T, Hayakawa H, Kanmatsuse K, Saitoh S, Saitoh T, Kamishima G, Watanabe K, Motomiya T, Murata M and et al. Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure. Cardiology. 1995;86:34-40.27.Stroshane RM, Koss RF, Biddlecome CE, Luczkowec C and Edelson J. Oral and intravenous pharmacokinetics of milrinone in human volunteers. J Pharm Sci. 1984;73:1438-41.28.DiBianco R. Clinical results with oral milrinone in heart failure. Eur Heart J. 1989;10 Suppl C:44-52.29.Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML and et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-75.30.Kaye DM, Nanayakkara S, Vizi D, Byrne MJ, Mariani JA.? Effects of Milrinone on Rest and Exercise Hemodynamics in Heart Failure with Preserved Ejection Fraction. Journal of the American College of Cardiology. 2016; 67(21):2553-2562.? AppendicesAppendix 1. Patient Informed Consent Template ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
Related searches
- sporadic inclusion body myositis cure
- sporadic inclusion body myositis symptoms
- treatment for inclusion body myositis
- inclusion body myositis diagnosis
- inclusion body myositis mayo clinic
- inclusion body myositis physical therapy
- inclusion body myositis progression
- inclusion body myositis symptoms
- is inclusion body myositis fatal
- what is inclusion body myositis
- inclusion body myositis and pain
- inclusion body myositis prognosis